Key role identified for enzymes in DNA replication and sensitivity to chemotherapeutic drugs

August 9, 2018, Institute for Research in Biomedicine (IRB Barcelona)
TLK inhibition leads to replication stress (green) and extensive DNA damage (red) in cultured cancer cells. Credit: Sandra Segura-Bayona, IRB Barcelona.

Loss of TLK1 and TLK2 results in extensive DNA damage during DNA replication and in cancer cell death. Depletion of TLK1/2 enhances the effectiveness of some chemotherapeutic agents currently being tested in clinical trials

During cell growth, cells copy their DNA through a process called DNA replication. For this process to be accurate, the genetic and must be copied flawlessly. In this regard, researchers led by Travis H. Stracker at the Institute for Research in Biomedicine (IRB Barcelona), in collaboration with Anja Groth's group at the Biotech Research & Innovation Centre (BRIC), have identified a key role for the TLK1 and TLK2 enzymes in DNA replication.

"We demonstrated that TLK activity is critical to prevent extensive DNA damage and cell death during DNA replication. And in some human cancers, TLK1 and TLK2 correlate with clinical outcome, thus supporting the idea that they may be promising targets for inhibition," explains Travis H. Stracker, head of the Genomic Instability and Cancer Lab.

Published in Science Advances, the study is based on previous studies that pointed to TLK1/2 as potential candidate targets in , and it provides new molecular details on their key functions in cancer cell proliferation.

This collaborative study has used state-of-the-art molecular approaches to analyze DNA replication and DNA damage, as well as the computational analysis of publicly available cancer data from the Cancer Genome Atlas (TCGA) project.

Fueling the faithful duplication of DNA

The scientists have demonstrated that TLK1 and TLK2 activity is crucial for regulating the availability of histones, abundant proteins that protect DNA, provide structure and carry epigenetic information. "When DNA is copied, cells need to provide twice as many histones and deposit them properly in order to maintain genetic and epigenetic information. If there are too few histones, crucial information is lost and DNA damage occurs," explains Sandra Segura-Bayona, Ph.D. student in the Genomic Instability and Cancer Lab and one of the first authors of the study.

Potential targets for cancer therapy

The researchers examined the status of the TLK1 and TLK2 genes in over 7000 patient samples made publically available by the Cancer Genome Atlas project. They found that these genes are rarely mutated in cancers, thereby suggesting a potentially conserved role. In many cases, the TLK1 and TLK2 genes were duplicated or overexpressed and in several types of cancer, high expression correlated with poor patient outcome.

Although previous studies had proposed that TLK1/2 were potential targets for breast cancer therapy, this study demonstrates that their inhibition could be useful for the treatment of various kinds of cancer and may enhance the activity of several chemotherapeutic agents currently in clinical trials. These enzymes therefore emerge as potential targets for future drug development.

Explore further: Researchers discover a crucial gene involved in the development of the placenta

More information: Sung-Bau Lee et al. Tousled-like kinases stabilize replication forks and show synthetic lethality with checkpoint and PARP inhibitors, Science Advances (2018). DOI: 10.1126/sciadv.aat4985

Related Stories

Researchers discover a crucial gene involved in the development of the placenta

July 17, 2017
A massive genomics study of people with intellectual disabilities performed in the Netherlands points to patient mutations in the TLK2 gene.

Scientists discover how satellite RNA leads to cancer

July 3, 2018
Only some of us have satellite TV in our homes, but all of us have satellite DNA in cells in our bodies. Working copies of satellite DNA (called satellite RNAs) are high in certain types of cancer, such as breast and ovarian. ...

Findings from breast and gynecological cancer study may have potential for future clinical applications

April 5, 2018
Researchers from The University of Texas MD Anderson Cancer Center have found a startling amount of new information about molecular features of tumors as well as identified previously unknown cancer subtypes based on a comprehensive ...

Recommended for you

Researchers find pathways that uncover insight into development of lung cancer

August 17, 2018
Lung cancer is the leading cause of preventable cancer death. A disease of complex origin, lung cancer is usually considered to result from effects of smoking and from multiple genetic variants. One of these genetic components, ...

Scientists discover new method of diagnosing cancer with malaria protein

August 17, 2018
In a spectacular new study, researchers from the University of Copenhagen have discovered a method of diagnosing a broad range of cancers at their early stages by utilising a particular malaria protein that sticks to cancer ...

Developing an on-off switch for breast cancer treatment

August 17, 2018
T-cells play an important role in the body's immune system, and one of their tasks is to find and destroy infection. However, T-cells struggle to identify solid, cancerous tumors in the body. A current cancer therapy is using ...

Pregnant? Eating broccoli sprouts may reduce child's chances of breast cancer later in life

August 16, 2018
Researchers at the University of Alabama at Birmingham have found that a plant-based diet is more effective in preventing breast cancer later in life for the child if the mother consumed broccoli while pregnant. The 2018 ...

Three scientists share $500,000 prize for work on cancer therapy

August 15, 2018
Tumors once considered untreatable have disappeared and people previously given months to live are surviving for decades thanks to new therapies emerging from the work of three scientists chosen to receive a $500,000 medical ...

PARP inhibitor improves progression-free survival in patients with advanced breast cancers

August 15, 2018
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.